A 19-year-old man with a high-grade osteosarcoma of the femur, treated with neoadjuvant chemotherapy, surgery, and adjuvant chemotherapy suffered from lung metastases 15 months after diagnosis. They were resected. Thirteen months later, he had vague abdominal complaints which, after analysis, proved to be caused by peritoneal metastasis. A review of the literature, possible physiopathological mechanisms of increased occurrence of unusual metastases and the role of bone scintigraphy in the follow-up of patients with osteosarcoma are discussed.
Introduction
Osteosarcoma is a primary malignant bone tumour, the neoplastic cells of which produce osteoid. It is the most common sarcoma of the bone and the second most common primary bone tumour, after multiple myeloma. Osteosarcoma typically occurs during childhood and adolescence. The male to female ratio is approximately 1.4 [1] . The peak incidence is reported to be between 10 and 19 years, whereas the mean and median are 29 and 20 years respectively. Osteosarcoma presenting at older age is usually associated with pre-existing conditions such as Paget's disease, irradiated bones and multiple hereditary exostosis. In Europe, the yearly incidence is 2.1 cases per million persons [2] .
The localisation of osteosarcoma is mainly at the metaphyses of long bones. The most frequently affected primary localisations are the distal femur (41.6%), proximal tibia (18.9%) and proximal humerus (10.7%) [3] .
At diagnosis, 80%-90% of patients have localized disease, while distant metastases can be identified in only 10%-20% [4] . Recurrent disease is observed in 30%-50% of patients [5] [6] [7] . Metastatic dissemination is haematogenous, although early lymphatic spread to regional lymph nodes has been reported [8] . In many cases, metastases are clinically and radiologically silent and detected only at autopsy. The sites of recurrence at autopsy are lung (98.1%), skeleton (37.0%), pleura (33.3%), heart (20.4%), kidney and liver (16.7%), diaphragm (14.8%) and mediastinum (11.1%). Lymph node involvement has been described in 7.4% [3] .
Early detection of pulmonary metastases is important, since complete surgical resection of all metastatic disease is a prerequisite for long-term survival after relapse [5, 7] .
A patient with an osteosarcoma of the femur, who, after a first relapse in the lungs, developed peritoneal metastasis is reported.
Case report
A 19-year-old man consulted the Department of Medical Oncology of the University Hospital of Antwerp because of pain and swelling of his left knee. No other complaints were present. His medical and family history were unremarkable. Physical examination was normal, except for a solid mass of 10 centimetre (cm) at the left lateral distal femur. No neurological deficits were found.
Haematological and biochemical laboratory tests revealed no abnormalities. Radiology of the left leg showed an osteolytic lesion with a Codman triangle at the distal femur. Magnetic resonance imaging (MRI) showed a diameta-epiphysial mass with joint invasion. A skip lesion was seen at 8.5 cm from the border of the tumour. Computerized tomography (CT) of the thorax and abdomen were normal. Bone scintigraphy showed a pathological area of increased uptake at the left distal femur.
A biopsy confirmed the diagnosis of osteosarcoma (T2N0M0, grade 3); no distant metastases were found.
Systemic neoadjuvant chemotherapy with cisplatin and doxorubicin combined with filgastrim was administered according to an EORTC protocol (EORTC-80931). After three cycles of chemotherapy, limb-sparing surgery, a closed-joint resection with insertion of a total-kneeprothesis was performed. Pathological investigation of the resected specimen showed a sclerotic-type osteosarcoma, without intratumoural necrosis. The presence of a skip lesion was confirmed. The borders of the specimen were tumour-free. After recovery and in ac-cordance with the protocol, three cycles of postoperative polychemotherapy were given and the patient went in follow-up.
Fifteen months after diagnosis, although the patient had no complaints and laboratory tests were normal, a retrosternal opacity was seen on chest radiography. A CT-scan of the chest suggested pulmonary metastases. Radiographic imaging of the left femur and knee showed partial recovery of the bone structures without signs of recurrent disease. Local surgical resection of four pulmonary nodules was performed by mid sternal thoracotomy and the diagnosis of lung metastases of osteosarcoma was confirmed.
Approximately 28 months after diagnosis, the patient had vague abdominal complaints with burning retrosternal pain and abdominal distention. Nausea and vomiting occurred occasionally.
On clinical examination, a painful solid mass was palpated in the epigastric region. Haematological tests were normal. Biochemical tests showed elevated alkaline phosphatase and lactate dehydrogenase.
On chest radiography, no abnormalities were seen. CT-scan and MRI of the abdomen showed a mass of 12x8 cm. The intensity and characteristics of this lesion were suggestive of bone and soft tissue. The mass partly compressed the stomach, liver, pancreas, truncus coeliacus and left kidney ( Figure 1) . A digital substraction angiography showed extrinsic compression of the hepatic artery without connection with the tumour. Bone scintigraphy demonstrated a pathological area of uptake in the left abdomen ( Figure 2 ).
The patient was treated with two cycles of polychemotherapy (cisplatin, doxorubicin and ifosfamide), which resulted in stable disease. Laparotomy revealed an inoperable peritoneal mass; pathological examination confirmed a metastasis of osteosarcoma.
The patient received further palliative care. He died due to progressive disease 36 months after diagnosis.
Discussion
Osteosarcoma is treated with ablative surgery and chemotherapy. Chemotherapy may eradicate micrometastases in a substantial proportion of patients, contributing to the increase in survival compared to surgery alone [5, 9, 10] . With current treatment protocols, the five-year survival rate in patients without overt metastastic disease at presentation has become more than 60%, ranging from 20% to 79% [11, 12] .
When pulmonary metastases develop, resection of the lung nodules may result in a five-year survival rate of 23% to 38% [6, 13] . The prognostic factors correlating with survival after metastasectomy are sex and number of nodules [6] . The survival of patients who developed lung metastases is longer after metastasectomy (13.4 months versus 8.1 months) [7] . Radiotherapy is recommended for palliation and selected situations.
Several authors have suggested that chemotherapy has changed the metastatic pattern of osteosarcoma. Lung metastases may appear later and may be fewer in number [6, 7, 9] . The site of first relapse may also be at unusual extrapulmonary sites [1] . After chemotherapy and surgery, pulmonary metastases are the only site of primary relapse in 87% of patients, while multiple sites or metastases in the skeleton are seen in 13% [7] . The patient reported here, developed lung metastases after a disease free interval (DFI) of 15 months, which is comparable with results in the literature (DFI: 11.5-21 months) [7, 5] . In second or third recurrences, metastatic disease may develop at multiple or unusual sites such as chest wall, diaphragm, lymph nodes, epidural space, brain, skin and heart. The interval between lung and peritoneal metastases was 13 months in our patient. In the literature, the mean interval between first and second relapse is about six months [7] .
Peritoneal metastases are very rare in osteosarcoma. Only four other reports have been published [14] [15] [16] . In one of these cases, a long-term survival of 53 months was reported, even though the patient presented with metastatic disease at diagnosis [17] .
Physiopathological mechanisms
Haematogenous metastasis is a complex process. A single cell or groups of cells dissociate from the primary tumour and invade the extracellular matrix. They enter the blood vessels, escape the immune surveillance and mechanical disruption and adhere to blood vessels at distant sites. After leaving the vascular system, they may proliferate to form a metastatic growth [18] .
Clinical studies have shown that malignant tumours frequently show a definite metastatic pattern. Organ specific modulation of tumour growth, mechanical entrapment and arrest by specific recognition between neoplastic cells and capillaries have all been suggested as mechanisms regulating specificity [20] .
Paget was the first to propose the hypothesis of 'seed and soil': only specific cells, compatible to a specific environment provided by particular organs are able to fulfil all the conditions for proliferation at distance [21] .
A second, mechanistic hypothesis states that organ specificity is the result of the anatomical localisation of the primary tumour. Haematogenous metastases will develop in organs, first encountered by the circulation [22] .
A third hypothesis has been derived from animal models. Entrapment of tumour cells and development of secondary growths may be determined by qualitative and quantitative differences in the ability of cells to adhere to vascular endothelium of paniculate organs [23] .
A neoplasm is not composed of an uniform population of cells. Certain subpopulations may have very distinct differences in phenotype. When tumour heterogeneity results in a selective advantage of a subpopulation of cells, a clonal dominance develops.
A change in relapse pattern may be due to selection of cells by changing phenotype, by spontaneous mutation or by chemotherapy.
Alteration of the phenotype of tumour cells may increase the number of cells able to enter the systemic circulation (mechanistic hypothesis), to metastasize to specific organs (seed and soil hypothesis) or to change their interaction with vascular endothelium (vascular adherence hypothesis), all giving rise to an altered metastatic pattern.
Chemotherapy may select slow growing clones, giving them more time to evolve in absence of more rapid growing tumour cells. These slow growing clones may have a different metastastic behaviour than fast growing ones.
Follow-up
In order to detect metastatic disease early, follow-up protocols of patients with osteosarcoma include history taking and physical examination at intervals, regular laboratory tests, local and chest radiographs, CT-scans of the chest and whole body bone scintigraphy. Local and chest radiographs as well as chest CT-scans are obtained at regular intervals, since the lungs and the skeletal system are the most frequent site of relapse. However, there is no uniform agreement on the need for bone scintigraphy. In some studies, bone scintigraphy is obtained at regular intervals, whereas in others, they are only performed if indicated.
Bone scintigraphy is a functional, metabolic investigation, in which a radionucleotide is coupled to a skeletal tracer, specifically taken up by bone tissue. The precise mechanism of uptake of 99n> Tc-methylenediphosphonate (MDP) is largely unknown, but the tracer is apparently bound to collagen contained in the bone matrix. This process is intensified in areas of increased blood-flow and bone remodelling [24] . In case of osteosarcomatous degeneration, it may reflect bone healing process rather than tumour viability itself [25] . The morbidity of bone scintigraphy is virtually nil. In adults, the radiation exposure is comparable to an abdominal radiograph, whereas in children and adolescents it may be two to four times higher.
A definite advantage is that the whole body is screened, while other techniques visualize only part the part of the body being studied. In a study by Caluser et al., 99m Tc-MDP bone scintigraphy in newly diagnosed or treated bone and soft tissue sarcomas had a sensitivity of 88%, a specificity of 38% and an accuracy of 74%. However, the data concerning osteosarcoma only, suggest a higher sensitivity (100%) than for the whole study group [25] . Bone scintigraphy is also a sensitive way of detecting local recurrences and bone metastases of osteosarcoma and is often the first investigation to be positive [26, 27] . Moreover, bone scintigraphy may show multiple sites, when on clinical and radiographic investigation only a single lesion is suspected [26] . Because different studies have shown contradictory results with regard to timing of the appearance of bone or local recurrence versus lung metastases, the role of bone scintigraphy in the follow-up remains a subject of debate.
Some authors suggest bone scintigraphy should only be done on symptomatic, clinical and radiographic indications. They state that lung metastases almost always preceded relapse in the bone and chest radiograph and CT-scan are more accurate in detecting lung metastases. Hence, if the latter investigations suggest lung metastases, bone scintigraphy should be obtained to detect bone or soft tissue metastases at other localisations [28, 29] .
In contrast, others authors suggest that bone scintigraphy should be done at regular intervals, since bone metastases are not infrequently found before the appearance of lung metastases [26, 30] . In a follow-up study of 33 patients with osteosarcoma, 21% had bone metastases as only presentation of metastastic disease or before the development of lung metastases [26] .
Moreover, with the general increase and longer survival of patients who develop lung metastases, which results in atypical metastases, the importance of bone scintigraphy may becoming more prominent. We suggest that in the follow-up of the patients in whom lung metastases have been removed, regular bone scintigraphies should be performed. This may detect earlier metastastic disease, which may be treatable by surgery. In our patient, due to the extent of local invasion, no resection was possible. Resection may have been possible by earlier intervention. However, the value of this approach should be tested in a prospective approach.
Conclusions
In patients with osteosarcoma, current treatment procedures including surgery and chemotherapy, sometimes in combination with pulmonary metastasectomy, have resulted in an increase in survival. It may however also result in an increase in selection pressure on the population of tumour cells, resulting in subpopulations with an atypical behaviour.
A follow-up protocol should aim to detect metastases at sites other than lung and skeleton, especially in patients successfully treated for lung metastases. A proposed timing of medical imaging investigations is shown in Table 1 .
Early detection of atypical metastases in the adrenal gland, kidney or peritoneum, may be important, because the possibility of curation by surgery. Furthermore, in case of relapse no longer amenable to curative treatment, a palliative approach may be instituted early if important clinical relevance e.g. gastrointestinal obstruction, is anticipated, which may improve the quality of life.
